RxDoctor Payments Data

Patricia Curtis-Mccarthy, PA

Physician Assistant · Euclid, OHNPI 1982668984

Payments from drug & device makers

$912in general payments, 2019–2025

Across 43 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$389
  • GSK$220
  • Sanofi-aventis U.S. LLC$100
  • Merck$61
  • Inogen, Inc.$61
  • Boehringer Ingelheim$60
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$81289%
  • Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi17$389
GSK14$220
Sanofi-aventis U.S. LLC1$100
Merck4$61
Inogen, Inc.3$61
Boehringer Ingelheim3$60
Regeneron Healthcare Solutions, Inc.1$22

How this compares

$912 in reported general payments places this provider in the 75th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$14,765
Medicare patients
72
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter125$108,112
Breztri AerosphereBudesonide/Glycopyr/Formoterol96$73,829
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$19,955
Advair HfaFluticasone Propion/Salmeterol31$16,744
Spiriva RespimatTiotropium Bromide18$12,480
SymbicortBudesonide/Formoterol Fumarate20$7,904
Incruse ElliptaUmeclidinium Bromide13$7,791
Albuterol Sulfate HfaAlbuterol Sulfate165$6,443
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,832
DuleraMometasone/Formoterol15$5,307
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$4,469
Roflumilast35$3,393
Omeprazole95$2,234
Wixela InhubFluticasone Propion/Salmeterol14$2,045
Mometasone Furoate13$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$220$135,858155 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$60$18,31330 claims
MerckDulera$61$5,30715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Euclid

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →